[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611684":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Secukinumab - HS",null,"Participants with Hidradenitis Supurativa who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.",[13],"Drug: Secukinumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Secukinumab - Pediatric plaque psoriasis","Participants with pediatric plaque psoriasis who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Secukinumab - JIA","Participants with juvenile idiopathic arthritis who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Secukinumab","This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.",[9,19,15],[29],"Cosentyx",[31],{"name":32,"affiliation":32,"role":33},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":10,"email":38},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":32,"role":36,"phone":10,"phoneExt":10,"email":10},[41],{"facility":42,"status":43,"city":44,"state":44,"zip":45,"country":46,"countryCode":10,"cosmosGeoPoint":47,"geoPoint":52,"contacts":10},"Novartis Investigative Site","RECRUITING","Seoul","06973","South Korea",{"type":48,"coordinates":49},"Point",[50,51],126.9784,37.566,{"lat":51,"lon":50},{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100611684","regulatory-post-marketing-surveillance-in-hidradenitis-suppurativa-pediatric-plaque-psoriasis-and-jia-treated-with-cosentyxsecukinumab-in-korea-100611684",false,"NCT07243782","Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea","Regulatory Post-Marketing Surveillance to Assess Safety and Effectiveness in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea : a rPMS Study","Inclusion Criteria:\n\nHidradenitis suppurativa:\n\n1. Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication.\n2. Patients who have agreed to participate in study (written informed consent)\n\nPediatric plaque psoriasis:\n\n1. Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication.\n2. Patients with patient or guardian consent to participate in study (written informed consent)\n\nJuvenile idiopathic arthritis:\n\n1. Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication.\n2. Patients with patient or guardian consent to participate in study (written informed consent)\n\nExclusion Criteria:\n\n1. Patients who are contraindicated according to national prescribing information\n2. Patients participating in other interventional clinical trials","ALL","6 Years","100 Years",{"count":66,"type":67},76,"ESTIMATED","OBSERVATIONAL","Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea",[71,72,73],"Hidradenitis Suppurativa","Pediatric Plaque Psoriasis","Juvenile Idiopathic Arthritis","2026-03-03",{"date":76,"type":77},"2026-03-05","ACTUAL",{"date":79,"type":77},"2025-12-22",{"date":81,"type":67},"2027-06-15",{"name":32,"class":6},1]